19 November 2021. JS016, a COVID-19 treatment with China’s independent intellectual property, has been approved for emergency use by 15 countries, with the combination of another neutralizing antibody.https://www.chinadaily.com.cn/a/202111/19/WS61970fbea310cdd39bc76513.html